Sphingotec GmbH
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 15, 2027The maintenance fee for Adrenomedullin assays and methods for determining mature adrenomedullin (US 11,726,101) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Selenoprotein P for prediction of a first cardiovascular event (US 11,844,812) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 2 fees due Sep 24 to 30, 2027 · next Sep 24
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 17 US 12,800,593 Method for Predicting the Risk of Incidence of Chronic Kidney Disease
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,228,581 | Adrenomedullin assays and methods for determining mature andrendomedullin In force · USPTO record | In force | USPTO record | |
| US 12,247,988 | Adrenomedullin assays and methods for determining mature andrendomedullin In force · USPTO record | In force | USPTO record | |
| US 11,726,101 | Adrenomedullin assays and methods for determining mature adrenomedullin In force · USPTO record | In force | USPTO record | |
| US 9,535,060 | Adrenomedullin assays and methods for determining mature adrenomedullin In force · USPTO record | In force | USPTO record | |
| US 9,664,695 | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction In force · USPTO record | In force | USPTO record | |
| US 9,702,876 | Method for Predicting the Risk of Getting Cancer or Diagnosing Cancer in a Female Subject In force · High confidence | In force | High confidence | |
| US 10,114,029 | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction In force · USPTO record | In force | USPTO record | |
| US 11,016,107 | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction In force · USPTO record | In force | USPTO record | |
| US 12,399,186 | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction In force · USPTO record | In force | USPTO record | |
| US 10,598,674 | Adrenomedullin to guide therapy of blood pressure decline In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 16: 4 patents in force now held by others · 7 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 2 abandoned · 14 no status recorded
Showing 1 to 10 of 24, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/148,633 | Treatment of Dementia or Alzheimer's an Anti-Adrenomedullin (ADM) Antibody or an Anti-Adrenomedullin Antibody Fragment | Dec 30, 2022 | Pending |
| 17/955,765 | Method for Predicting the Risk of Getting Cancer or Diagnosing Cancer in a Female Subject | Sep 29, 2022 | Pending |
| 18/568,334 | A Method for Predicting Sepsis and Septic Shock | Jun 17, 2022 | Pending |
| 18/289,612 | May 6, 2022 | No status recorded | |
| 17/201,518 | Pro-Adrenomedullin or Fragment Thereof in Patients Infected with Corona Virus and Treatments with Binder Against Adrenomedullin | Mar 15, 2021 | Pending |
| 17/131,008 | Method for Predicting the Risk of Getting Cancer or Diagnosing Cancer in a Female Subject | Dec 22, 2020 | Pending |
| 17/635,265 | A Method for Diagnosing or Monitoring Kidney Function or Diagnosing Kidney Dysfunction in Pediatric Patients | Aug 14, 2020 | Pending |
| 16/895,169 | Jun 8, 2020 | No status recorded | |
| 16/781,226 | Feb 4, 2020 | No status recorded | |
| 16/748,298 | Jan 21, 2020 | No status recorded |
10 of 24 applications shown.
Pro members see all 24 published applications.